APOA2

Apolipoprotein A-II is the second most abundant protein of high-density lipoproteins, synthesized as a prepro-protein (18-aa signal peptide plus 5-aa propeptide) that matures into a homodimer of two 77-residue chains linked by a Cys-6 disulfide bridge (PMID:4338591, PMID:6328445). On HDL particles, apoA-II forms mixed disulfide complexes with apoE (PMID:210174), serves as an acceptor for ABCA1-mediated cholesterol and phospholipid efflux with nanomolar-range binding affinity (PMID:11162594), and restricts the association of LCAT and cholesteryl ester transfer activities to apoA-II-containing particles (PMID:3104518). APOA2 pre-mRNA splicing is regulated by TDP-43, which silences exon 3 inclusion by binding a (GU)₁₆ intronic element, while promoter methylation at the -265T>C polymorphism modulates APOA2 expression in a saturated-fat-intake-dependent manner (PMID:16254078, PMID:29901700). In hepatocellular carcinoma, APOA2 overexpression drives TGF-β-dependent endothelial-mesenchymal transition, lipid metabolic reprogramming, and antiangiogenic drug resistance, and APOA2 protein interacts with PD-L1 to modulate the tumor immune microenvironment (PMID:41760604, PMID:38886351).

1. 1972 High

   Determining the primary structure of apoA-II established it as a disulfide-linked homodimer of 77-residue chains, defining the fundamental architecture of the second major HDL apolipoprotein.

   Evidence Protein isolation from human HDL and complete amino acid sequencing

   PMID:4338591

   Open questions at the time

   • No three-dimensional structure determined
   • Lipid-binding mechanism and amphipathic helix arrangement unresolved
   • Biological function of the disulfide linkage unknown
2. 1978 High

   Discovery of a mixed apoE–apoA-II disulfide complex in plasma lipoproteins revealed that apoA-II participates in inter-apolipoprotein covalent interactions, suggesting it modulates HDL composition beyond simple structural scaffolding.

   Evidence Biochemical isolation and characterization of the disulfide complex from human plasma HDL subfractions

   PMID:210174

   Open questions at the time

   • Functional consequence of apoE–apoA-II complex formation on lipoprotein metabolism unknown
   • Stoichiometry and regulation of complex formation not defined
3. 1984 High

   cDNA cloning revealed that apoA-II is synthesized as a prepro-protein with an 18-aa signal peptide and a 5-aa propeptide, establishing its secretory biosynthetic pathway.

   Evidence cDNA cloning and nucleotide sequencing of human APOA2

   PMID:6328445

   Open questions at the time

   • Propeptide cleavage protease not identified
   • Tissue-specific regulation of APOA2 transcription not characterized
4. 1986 High

   Demonstration that LCAT and cholesteryl ester transfer activities preferentially associate with apoA-I-only HDL particles established apoA-II as a negative modulator of HDL cholesterol esterification and transfer, clarifying a long-debated functional distinction between HDL subclasses.

   Evidence Immunoaffinity fractionation of HDL subpopulations with LCAT and CET activity assays in human plasma

   PMID:3104518

   Open questions at the time

   • Direct molecular mechanism by which apoA-II excludes LCAT/CET activity not elucidated
   • In vivo metabolic consequences of altered LCAT partitioning not tested
5. 2001 High

   Showing that apoA-II binds ABCA1 with affinity comparable to apoA-I and mediates cholesterol/phospholipid efflux broadened the understanding of ABCA1 beyond apoA-I, positioning apoA-II as a physiological lipid acceptor in reverse cholesterol transport.

   Evidence Cholesterol and phospholipid efflux assays and specific binding measurements in ABCA1-GFP-transfected HeLa cells

   PMID:11162594

   Open questions at the time

   • Relative in vivo contribution of apoA-II versus apoA-I to ABCA1-mediated efflux not quantified
   • Whether apoA-II-containing nascent HDL particles have distinct downstream fates is unknown
6. 2005 High

   Identification of TDP-43 as a splicing silencer of APOA2 exon 3 uncovered a post-transcriptional control layer for apoA-II expression, showing that a ubiquitous RNA-binding protein governs alternative splicing of this liver-expressed gene.

   Evidence siRNA knockdown of TDP-43, in vitro splicing, UV cross-linking/immunoprecipitation, and cis-element mutagenesis

   PMID:16254078

   Open questions at the time

   • Physiological signals that modulate TDP-43's splicing activity on APOA2 not identified
   • Consequences of exon 3 inclusion/skipping on apoA-II protein function not characterized
7. 2018 High

   Demonstrating that the -265T>C promoter polymorphism interacts with saturated fat intake to alter CpG methylation and APOA2 expression provided a gene-environment epigenetic mechanism for inter-individual variation in apoA-II levels.

   Evidence Epigenome-wide methylation, transcriptomic, and metabolomic analyses replicated across three independent cohorts

   PMID:29901700

   Open questions at the time

   • Causal direction of methylation–expression relationship not established by intervention
   • How altered apoA-II levels translate to downstream changes in tryptophan and BCAA metabolism is mechanistically undefined
8. 2024 Medium

   Discovery that SAMD4B destabilizes APOA2 mRNA via 2'-O-methylation and that reduced apoA-II decreases PD-L1 through a direct protein interaction revealed an unexpected immunoregulatory role for apoA-II in the tumor microenvironment.

   Evidence 2'-O-methylation assays, multiplex immunofluorescence, single-cell RNA-seq in PDX mouse models, and protein interaction assays in hepatocellular carcinoma

   PMID:38886351

   Open questions at the time

   • Direct apoA-II–PD-L1 binding interface not structurally characterized
   • Specificity of the 2'-O-methylation mechanism to APOA2 versus other mRNAs not assessed
   • Independent replication in a second laboratory pending
9. 2025 Low

   Computational spatial transcriptomics linked APOA2 to impaired dendritic cell antigen presentation via PPAR signaling in HCC, but this remains a correlative observation without direct functional validation.

   Evidence Spatial transcriptomics, single-cell RNA-seq, hdWGCNA, and CellChat analysis in hepatocellular carcinoma tissues

   PMID:41158225

   Open questions at the time

   • No in vitro or in vivo functional experiment directly testing apoA-II's effect on dendritic cell MHC expression
   • PPAR pathway link is inferred computationally without pharmacological or genetic perturbation
   • Single study without independent cohort replication
10. 2026 Medium

    In vivo overexpression showed that apoA-II drives antiangiogenic drug resistance in HCC by upregulating TGF-β, which induces endothelial-mesenchymal transition and lipid metabolic reprogramming, and TGF-β inhibition reverses these effects.

    Evidence APOA2 overexpression in mouse HCC models with whole transcriptome sequencing, proteomics, and pharmacological TGF-β inhibition

    PMID:41760604

    Open questions at the time

    • Mechanism by which apoA-II upregulates TGF-β secretion is unknown
    • Whether this cancer-context role reflects a physiological function of apoA-II in non-malignant tissue is untested
    • Confirmation in patient-derived models or clinical samples needed

• The structural basis by which apoA-II modulates LCAT and CET activity on HDL, the physiological significance of the apoE–apoA-II disulfide complex, and whether apoA-II's newly described immunomodulatory and TGF-β-related activities in cancer operate through the same lipid-binding surfaces used in lipoprotein metabolism remain unresolved.
• No high-resolution structure of lipid-bound apoA-II dimer
• Relative in vivo contribution of apoA-II to reverse cholesterol transport versus apoA-I not quantified
• Mechanistic link between apoA-II's lipid-binding properties and its cancer-associated signaling roles undefined